NEW YORK, (GLOBE NEWSWIRE) - Ovid Therapeutics Inc. NEW YORK, May 01, (GLOBE NEWSWIRE via COMTEX).
Transaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales Ovid to invest $10 million in preferred equity in Graviton and will fund development programs The MarketWatch News Department was not involved in the creation of this content.Ĭollaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseasesĬouples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programsĭevelopment to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizures
0 kommentar(er)
